CoChat
Sign Up
Cited by 250Sexual function and dysfunction studiesHormonal and reproductive studiesMenopause: Health Impacts and Treatments

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial

Davis, Susan R., van der Mooren, M. J., van Lunsen, Rik H. W., Lopes, Patrice, Ribot, Jean, Rees, Margaret, Moufarege, Alain., Rodenberg, Cynthia, Buch, Akshay, Purdie, David. W.·2006·Menopause
DOI 10.1097/01.gme.0000179049.08371.c7
Open this paper in CoChat — free account

Abstract

In Brief Objective: Evaluation of the use of testosterone therapy for hypoactive sexual desire disorder (HSDD) after oophorectomy has mostly involved women treated with oral estrogen preparations. We investigated the efficacy and safety of a testosterone patch in surgically menopausal women receiving concurrent transdermal estrogen. Design: Women with HSDD after oophorectomy, for whom this was a concern, who were using transdermal estrogen, were recruited to a 24-week, randomized, double-blind, placebo-controlled trial in Europe and Australia. Patients were randomly allocated to placebo (n = 40) or testosterone 300 μg/day (n = 37) treatment. Primary endpoints were changes in sexual desire measured by the sexual desire domain of the Profile of Female Sexual Function and the frequency of satisfying sexual activity at 24 weeks. Results: Sixty-one women (79%) completed the trial. All subjects who received at least one application of study medication were included in analysis. The testosterone-treated group experienced a significantly greater change from baseline in the domain sexual desire score compared with placebo (change from baseline, 16.43 versus 5.98; P = 0.02). The domain scores for arousal, orgasm, decreased sexual concerns, responsiveness, and self-image as well as decreased distress were also significantly greater with testosterone therapy than placebo. The frequency of satisfactory sexual events increased but was not statistically different between treatment groups (P = 0.06) Adverse events occurred with similar frequency in both groups, and no serious risks of therapy were observed Conclusions: In this study, transdermal testosterone therapy via a skin patch improved sexual desire and other sexual function domains. It was well tolerated in these oophorectomized women with HSDD receiving concomitant transdermal estrogen. Published studies of testosterone therapy for surgically menopausal women have mostly involved concurrent oral estrogen therapy. In this trial, oophorectomized women with low sexual desire using transdermal estradiol therapy were treated with transdermal testosterone therapy or placebo. Testosterone therapy significantly improved sexual desire and other sexual function domains versus placebo and was well tolerated.

Overview

Integrity signals

Registry

Crossref · 10.1097/01.gme.0000179049.08371.c7

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Davis, S. R., van der Mooren, M. J., van Lunsen, R. H. W., Lopes, P., Ribot, J., Rees, M., Moufarege, A., Rodenberg, C., Buch, A., & Purdie, D. W.
Affiliations
  • Jean Hailes (AU)
  • Hôpital Rangueil (FR)
  • John Radcliffe Hospital (GB)
  • Procter & Gamble (United Kingdom) (GB)
  • Procter & Gamble (United States) (US)
Corresponding author
Davis, Susan R.
ORCID
Davis, Susan R.
Venue
Menopause
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2006-05
Volume
13
Issue
3
Pages
387-396
ISSN
1072-3714 (ISSN-L)
DOI
10.1097/01.gme.0000179049.08371.c7
OpenAlex
W2799667742
Cited by
250
References
32
Citations by year
2026: 2 · 2025: 4 · 2024: 2 · 2023: 9 · 2022: 6 · 2021: 10 · 2020: 11 · 2019: 7 · 2018: 13 · 2017: 13 · 2016: 15 · 2015: 7 · 2014: 11 · 2013: 8 · 2012: 18
FWCI
16.57
Type
journal article
Language
en
Open access
closed
Locations
  • Menopause The Journal of The North American Menopause Society (publishedVersion)
  • PubMed (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Sexual function and dysfunction studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
Keywords
testosterone replacement therapy, hypoactive sexual desire disorder, oophorectomy, transdermal estradiol, sexual desire, female sexual function, treatment safety
MeSH terms
Administration, Cutaneous, Adult, Aged, Double-Blind Method, Estradiol, Female, Humans, Libido, Menopause, Premature, Middle Aged, Ovariectomy, Sexual Dysfunction, Physiological, Testosterone, Treatment Outcome, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review